Cartesian Therapeutics, Inc, a clinical─stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, announced that the first...
Vous n'êtes pas connecté
- English
- Français
- عربي
- Español
- Deutsch
- Português
- русский язык
- Català
- Italiano
- Nederlands, Vlaams
- Norsk
- فارسی
- বাংলা
- اردو
- Azərbaycan dili
- Bahasa Indonesia
- Հայերեն
- Ελληνικά
- Bosanski jezik
- українська мова
- Íslenska
- Türkmen, Түркмен
- Türkçe
- Shqip
- Eesti keel
- magyar
- Қазақ тілі
- Kalaallisut ; kalaallit oqaasii
- Lietuvių kalba
- Latviešu valoda
- македонски јазик
- Монгол
- Bahasa Melayu ; بهاس ملايو
- ဗမာစာ
- Slovenščina
- тоҷикӣ ; toğikī ; تاجیکی
- ไทย
- O'zbek ; Ўзбек ; أۇزبېك
- Tiếng Việt
- ភាសាខ្មែរ
- རྫོང་ཁ
- Soomaaliga ; af Soomaali
Maroc - PHARMABIZ.COM - A la Une - 28/Jun 00:00
University of Nebraska Medical Center enrolls patient for RenovoRx's pivotal phase III TIGeR─PaC trial
RenovoRx, Inc, a clinical─stage biopharmaceutical company developing novel precision oncology therapies based on a local drug─delivery platform, announced that the University of Nebraska Medical Center
Articles similaires
Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration Advances to Both Single-dose of 4mg and Multiple-dose of 3mg
drugs.com - 02/Jul 04:07
DAEJEON, South Korea, July 2, 2024. PharmAbcine, Inc. ("PharmAbcine" or the "Company") (KOSDAQ: 208340), a clinical-stage public company developing...
Synaptogenix gets US FDA authorization of IND application for clinical trial for Bryostatin─1 to treat multiple sclerosis
pharmabiz.com - 01/Jul 00:00
Synaptogenix, Inc., an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, announced that the Food & Drug...
First Patient Dosed in the MAD Part 2 Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
drugs.com - 26/Jun 19:06
CAMBRIDGE, Mass., June 26, 2024. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on transforming cardiometabolic...
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation Granted to SLS009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia
drugs.com - 24/Jun 23:06
NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a...
First Patient Dosed in Phase 2 Trial of Descartes-08 in Systematic Lupus Erythematosus
drugs.com - 03/Jul 04:07
GAITHERSBURG, Md., July 02, 2024. artesian Therapeutics, Inc. (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell...
Veru to Participate in the Leerink Therapeutics Forum: I&I and Metabolism
mangaloremirror.com - 02/Jul 12:51
MIAMI, FL, July 02, 2024 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing...
Syneos Health - USA: Principal Clinical Trial Manager - Early Phase
pharmiweb.com - 28/Jun 00:00
Competitive: Syneos Health - USA: Principal Clinical Trial Manager - Ophthalmology Syneos Health® is a leading fully integrated biopharmaceutical...
MindMed to be Included in Russell 2000® and Russell 3000® Indexes
financialpost.com - 28/Jun 11:07
NEW YORK — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the “Company” or “MindMed”), a clinical stage biopharmaceutical...
Imugene delivers first combo dose in bile tract cancer study
thewest.com.au - 24/Jun 08:20
Imugene has confirmed the delivery of its first “onCARlytics” combination therapy dose to a bile duct cancer patient in the initial phase of a...
Les derniers communiqués
-
Aucun élément